Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017 - MarketsandMarkets

Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017

Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017 - MarketsandMarkets
Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017
Published Apr 03, 2013
360 pages — Published Apr 03, 2013
Price US$ 4,650.00  |  Buy this Report Now

About This Report

  
Abstract:



The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lion's share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope. Furthermore, the PET market will witness a double digit growth during the forecast period. The therapeutic segment contributes only 10% to the global radiopharmaceuticals market and I-131 has been considered as the gold standard for various oncology treatments in a combined therapy. Global nuclear medicines market is majorly driven by the increasing adoption of PET and SPECT scanners, and rising awareness for radiopharmaceuticals, whereas short half life of isotopes and stringent regulations are the factors that are hindering the growth of radiopharmaceuticals worldwide.

Besides highly preferred isotopes such as Tc-99m and F-18, significant growth is witnessed for Tl-201 and Rb-82 in diagnostic market and Y-90 and Lu-177 in beta therapy radioisotopes market. Exhaustive pipeline analysis reveals that coronary heart disease, Alzheimer's disease, breast cancer, and bone metastasis will drive the diagnostic radiopharmaceuticals market, whereas lymphoma, prostate cancer, bone metastasis, and hepatocellular carcinoma will boost the future of therapeutic radiopharmaceuticals. Besides new applications, the potential molecules that are expected to drive the market include Alpharadin (Ra-223), Ga-68, F-18 florbetapir, and F-18 choline. Though Ra-223 application is still under clinical trial, the market is highly optimistic regarding its clinical efficiency in prostate cancer, and bone metastasis.

North America held the largest share in the global radiopharmaceuticals market. The U.S. market is highly supported by the Mo-99 production of NRU reactor (Canada) and ongoing researches in different clinical institutes such as National Cancer Institute, Avid Radiopharmaceuticals and so on. Besides developed markets, the Asia-Pacific region is expected to show a remarkable growth in the coming years. China, India, Japan, South Korea, Brazil, and South Africa are expected to show a high growth potential amongst the emerging geographies. These countries are influenced by the domestic production of isotopes by reactors and government initiatives.

Apart from upcoming isotopes and their applications, understanding of the interlinked supply chain was imperative for market estimation. Value chain analysis and pipeline analysis have taken care of such business issues to come up with a consolidated market analysis, including the present and future impact of different factors. Demand and supply analysis identifies the potential risk of the interrupted supply of Mo-99 for the Tc-99m production, due to scheduled shutdown of major reactors and the benchmarking trend adopted by leading players to combat such operational difficulties.

The radiopharmaceutical market has been analyzed from both the radiopharmaceuticals processors' and generator manufacturer's perspectives. It has been identified that shifting from HEU to LEU is the major strategy in the processors market, while strengthening the supply chain of radiopharmaceuticals is the prime concern for the generator manufacturers.

In addition to the market size and forecast for radioisotopes, the report also covers competitive landscape and key developments of major players, pipeline analysis, investment opportunities, and regulatory affairs for established players as well as new entrants.

Custom Research/Customization details

RADIOPHARMACEUTICALS MARKET

1. PET and SPECT procedural volume (No. of procedures) at regional level and by Isotope

Estimation of diagnostic and therapeutic procedures in North America, Europe, Asia, and

  
Source:
Document ID
PH 1860
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

Title


Table Of Contents

1 Introduction (Page No. - 28)
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary (Page No. - 35)

3 Market Overview (Page No. - 40)
3.1 Definition Of Radiopharmaceuticals
3.2 Evolution
3.3 Market Segmentation
3.3.1 Radiopharmaceuticals
3.3.2 Stable Isotopes
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand For Radiopharmaceuticals
3.4.1.2 Increasing Use Of Spect And Pet Scans Results In Rise Of Radiopharmaceutical Usage
3.4.1.3 Rising Awareness Of Radiopharmaceuticals To Spur Growth
3.4.1.4 Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
3.4.2 Restraints
3.4.2.1 Shorter Half-Life Of Radiopharmaceuticals Restricts Its Usage
3.4.2.2 High Capital To Limit The Buying Of Scanners
3.4.2.3 Stringent Regulatory Guidelines And Gmp To Negatively Impact Growth
3.4.2.4 Competition From Conventional Diagnostic Procedures
3.4.3 Opportunities
3.4.3.1 Potential Radioisotopes In The Pipeline
3.4.3.2 High Demand In Emerging Countries
3.4.3.3 Alpha Radio Immunotherapy-Based Targeted Cancer Treatment
3.4.3.4 Alternative Diagnostic Radiopharmaceutical Solutions
3.4.3.5 Cyclotron Based Production
3.4.3.6 Neurological Applications
3.4.4 Threat
3.4.4.1 Shutdown Of Nuclear Reactors To Impact Production Of Radioisotopes
3.5 Winning Imperatives
3.5.1 Investments On New Radioisotopes And Novel Applications
3.5.2 Shift Towards Leu-Based Mo-99 Production
3.6 Burning Issues
3.6.1 High Cost Of Pet Cameras
3.6.2 Shortage In Supply Of Technetium-99m
3.7 Market Share Analysis
3.7.1 Radiopharmaceuticals Market
3.7.2 Enriched Stable Isotopes Market
3.8 Value Chain Analysis
3.8.1 Spect (Molybdenum-99/Technetium-99m)
3.8.1.1 Pricing Structure In Different Phases Of The Value Chain
3.8.1.2 Cost Modeling - Leu Based Tc-99m Production
3.8.2 Pet (Fluorine-18)
3.8.3 Stable Isotope (DEUTERIUM)
3.9 Pipeline Analysis
3.9.1 Diagnostic Radioisotopes
3.9.2 Therapeutic Radioisotopes
3.10 Demand & Supply Analysis
3.10.1 Demand For Mo-99/Tc-99m
3.10.1.1 Availability Of Spect Cameras To Stabilize Demand
3.10.1.2 Stringent Regulatory And Reimbursement Procedures For Alternative Isotopes Prevents Shift From Tc-99
3.10.1.3 Emerging Markets Will Enhance Usage Of Tc-99m
3.10.1.4 Potential Growth Of Tc-99m Based Diagnostic Imaging
3.10.1.5 Shift From Spect To Pet
3.10.2 Current Status Of Mo-99 Supply
3.11 Strategic Benchmarking
3.11.1 Processors' Shift From Heu To Leu Based Mo-99
3.11.1.1 Contract Extension By Nordion With Aecl & Supply Agreement With Riar
3.11.1.2 Agreement Of Covidien & Iae Polatom With Maria Reactor
3.11.1.3 Agreement Of Ntp Radioisotopes With Lantheus Medical Imaging
3.11.2 Sustainable Supply Chain By Generators
3.11.2.1 Contract Extension Of Lantheus Medical Imaging Inc., With Ntp Radioisot

Table Of Contents

MarketsandMarkets—Worldwide, market research reports primarily sold for numbers, market segmentation and competitive landscape, within the business leaders.

About the Author


Cite this Report

  
MLA:
MarketsandMarkets. "Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017" Apr 03, 2013. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/MarketsandMarkets/Nuclear-Medicine-Radiopharmaceuticals-SPECT-PET-Radioisotopes-Technetium-F-18-Beta-Alpha-radiation-therapy-I131-Y-90-Applications-Cancer-Oncology-Cardiac-Stable-Isotopes-Deuterium-C-13-Market-Global-Trends-Forecast-to-2017-2144-87>
  
APA:
MarketsandMarkets. (2013). Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017 Apr 03, 2013. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/MarketsandMarkets/Nuclear-Medicine-Radiopharmaceuticals-SPECT-PET-Radioisotopes-Technetium-F-18-Beta-Alpha-radiation-therapy-I131-Y-90-Applications-Cancer-Oncology-Cardiac-Stable-Isotopes-Deuterium-C-13-Market-Global-Trends-Forecast-to-2017-2144-87>
  
US$ 4,650.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.